Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab +1 More for Esophageal Cancer
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing a new cancer treatment combining NT-I7 with nivolumab to see if it is safe and effective in treating gastric or gastro-esophageal junction (GEJ) or esophageal adenocarcinoma (EAC). The study will first assess safety in escalating doses to find the maximum tolerated dose (MTD) or the recommended Phase 2 dose (RP2D). If the treatment is well tolerated, the study will then continue in Phase 2 to preliminary assess the antitumor activity and long-term survival of the treatment combination.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service